Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Gastrointestinal Metabolic Disorders Puerto Rico

GSK disputes '60 Minutes' report's implication of harm

This article was originally published in Scrip

Executive Summary

GlaxoSmithKline strongly rebutted implications made in the CBS TV programme 60 Minutes that patients were harmed as a result of manufacturing violations at its now-closed Cidra, Puerto Rico facility. The CBS programme reported 2 January more details about the $750 million GSK agreed to pay in October 2010 to settle US charges of manufacturing and distribution of adulterated drugs. GSK said it regretted the manufacturing violations at the facility highlighted in the CBS report, and emphasised that the problems took place between 2001 and 2005 and involved only one of the firm's manufacturing sites, which was run by its subsidiary SB Pharmco Puerto Rico.

Table

View full table

Topics

Related Companies

Tags:
Gastrointestinal Metabolic Disorders Puerto Rico
Latest Headlines

Navigating A Transition Year: Five Takeaways From Pfizer’s Q1 Call

Astellas Stakes Claim In CAR-Ts For Solid Tumors With Poseida Deal

Pharma Happy To Be Custodian For Innovative Science From Cash-Strapped Biotechs

GSK Looks Forward To RSV Vaccine Competition

See All
UsernamePublicRestriction

Register

SC011335

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By